4/16/2023 0 Comments Courseforum julia devlin![]() ![]() The use of retrospective data means that clinical practice (e.g. not considered part of routine management, whether or not related to multiple myeloma, such as unscheduled hospitalization, AEs, fractures) accounted for 1-9% of total costs and were highest for bendamustine. Mean cost per month was lowest for patients achieving a very good partial response or better. During active treatment, the highest costs were associated with lenalidomide- and pomalidomide-based regimens. Mean total healthcare costs associated with a single line of treatment were €51,717 in the UK, €37,009 for France, and €34,496 for Italy, driven largely by anti- myeloma medications costs (contributing 95.0%, 90.0%, and 94.2% of total cost, respectively). Physicians provided data for 1,282 patients (387 in the UK, 502 in France, 393 in Italy) who met the inclusion criteria. Costs were calculated based on HRU and country-specific diagnosis-related group and/or unit reference costs, amongst other standard resources. In the 3 months before record abstraction, eligible patients had either disease progression after receiving one of their country's most commonly prescribed regimens or had received the best supportive care and died. Data collection started on Jand was completed on July 15, 2015. Retrospective medical chart review of characteristics, time to progression, level of response, HRU during treatment, and adverse events (AEs). To assess the real-world healthcare resource utilization (HRU) and costs associated with different treatment regimens used in the management of patients with relapsed multiple myeloma in the UK, France, and Italy. Gonzalez-McQuire, Sebastian Yong, Kwee Leleu, Henri Mennini, Francesco S Flinois, Alain Gazzola, Carlotta Schoen, Paul Campioni, Marco DeCosta, Lucy Fink, Leah ![]() Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. These guidelines should be read in conjunction with the BCSH/UKMF Guidelines for the Diagnosis and Management of Multiple Myeloma 2011. Although most aspects of supportive care can be supervised by haematology teams primarily responsible for patients with multiple myeloma, multidisciplinary collaboration involving specialists in palliative medicine, pain management, radiotherapy and surgical specialities is essential, and guidance is provided for appropriate interdisciplinary referral. Written on behalf of the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum (UKMF), these evidence based guidelines summarize the current national consensus for supportive and symptomatic care in multiple myeloma in the following areas pain management, peripheral neuropathy, skeletal complications, infection, anaemia, haemostasis and thrombosis, sedation, fatigue, nausea, vomiting, anorexia, constipation, diarrhoea, mucositis, bisphosphonate-induced osteonecrosis of the jaw, complementary therapies, holistic needs assessment and end of life care. Maintenance of quality of life presents challenges at all stages of the disease from diagnosis through the multiple phases of active treatment to the end of life. While modern treatments have significantly prolonged overall and progression free survival through improved disease control, the vast majority of patients remain incurable, and live with the burden of the disease itself and the cumulative side effects of treatments. Supportive care plays an increasingly important role in the modern management of multiple myeloma. Snowden, John A Ahmedzai, Sam H Ashcroft, John D'Sa, Shirley Littlewood, Timothy Low, Eric Lucraft, Helen Maclean, Rhona Feyler, Sylvia Pratt, Guy Bird, Jennifer M Guidelines for supportive care in multiple myeloma 2011. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |